Processa amends 8-K to add Vidya Therapeutics financials from acquisition

Processa Pharmaceuticals, Inc. filed Amendment No. 1 to a Form 8-K on October 5, 2026, revising a Current Report originally filed on July 29, 2026 that had disclosed the completion of the acquisition of Vidya Therapeutics, Inc., a Delaware corporation.¹

The amendment adds financial disclosures that were not included in the original filing. It incorporates audited financial statements of Vidya Therapeutics for fiscal years 2025 and 2024, along with unaudited interim financial statements covering the first half of 2026 and the comparable period in 2025. The amendment also adds unaudited pro forma condensed consolidated financial information for Processa covering the same six-month period in 2026 and the full 2025 fiscal year.¹

The filing notes that Vidya was the entity holding all of the acquired assets, which is why the financial statements are presented for Vidya specifically.¹ Beyond the financials, the amendment incorporates by reference business and risk factor information related to Vidya.¹ Processa confirmed that this amendment does not change any other item of the original report.¹

Supporting exhibits include audited financial statements of Vidya for the years ended December 31, 2025 and 2024¹ and unaudited interim condensed consolidated financial statements of Vidya for the six months ended June 30, 2026 and 2025¹, along with unaudited pro forma condensed combined financial information for the company covering the same periods.¹ The underlying merger agreement, dated July 28, 2026, involved Processa Pharmaceuticals, Venus Merger Sub I, Venus Merger Sub II, and Vidya Therapeutics.¹ The report was signed by Chief Financial Officer Russell Skibsted.